New trends in anti-cancer therapy: Combining conventional chemotherapeutics with novel immunomodulators

Current Medicinal Chemistry

Volumn 25, Issue 36, 2018, Pages 4758-4784

  Wilson, Amy L ^a,b   Plebanski, Magdalena ^b   Stephens, Andrew N ^a,b,c  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c EPWORTH HEALTHCARE   (Australia)

Author keywords

CD137; Chemotherapy; CTLA 4; Immunomodulation; Immunotherapy; PD 1; PD l1

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMMUNE CHECKPOINT INHIBITOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 9; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85058876344     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170830094922     Document Type: Review

References (219)

1. Redman, J.M.; Hill, E.M.; AlDeghaither, D.; Weiner, L.M. Mechanisms of action of therapeutic antibodies for cancer. Mol. Immunol., 2015, 67(2 Pt A), 28-45.
2. Horn, T.; Laus, J.; Seitz, A.; Maurer, T.; Schmid, S.; Wolf, P.; Haller, B.; Winkler, M.; Retz, M.; Nawroth, R. The prognostic effect of tumour-infiltrating lymphocytic sub-populations in bladder cancer. World J. Urol., 2016, 34(2), 181-187.
3. Kim-Schulze, S.; Kim, H.S.; Fan, Q.; Kim, D.W.; Kaufman, H.L. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol. Ther., 2009, 17(2), 380-388.
4. Tan, J.T.; Ernst, B.; Kieper, W.C.; LeRoy, E.; Sprent, J.; Surh, C.D. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med., 2002, 195(12), 1523-1532.
5. Gattinoni, L.; Finkelstein, S.E.; Klebanoff, C.A.; Antony, P.A.; Palmer, D.C.; Spiess, P.J.; Hwang, L.N.; Yu, Z.; Wrzesinski, C.; Heimann, D.M.; Surh, C.D.; Rosenberg, S.A.; Restifo, N.P. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med., 2005, 202(7), 907-912.
6. Hardwick, N.; Frankel, P.H.; Cristea, M. New approaches for immune directed treatment for ovarian cancer. Curr. Treat. Options Oncol., 2016, 17(3), 14.
7. Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; Akerley, W.; van den Eertwegh, A.J.; Lutzky, J.; Lorigan, P.; Vaubel, J.M.; Linette, G.P.; Hogg, D.; Ottensmeier, C.H.; Lebbé, C.; Pe-schel, C.; Quirt, I.; Clark, J.I.; Wolchok, J.D.; Weber, J.S.; Tian, J.; Yellin, M.J.; Nichol, G.M.; Hoos, A.; Urba, W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 2010, 363(8), 711-723.
8. Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; Gilson, M.M.; Wang, C.; Selby, M.; Taube, J.M.; Anders, R.; Chen, L.; Korman, A.J.; Pardoll, D.M.; Lowy, I.; Topalian, S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol., 2010, 28(19), 3167-3175.
9. Pauken, K.E.; Wherry, E.J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol., 2015, 36(4), 265-276.
10. Mahdi, H.; Elshaikh, M.A.; DeBenardo, R.; Munkarah, A.; Isrow, D.; Singh, S.; Waggoner, S.; Ali-Fehmi, R.; Morris, R.T.; Harding, J.; Moslemi-Kebria, M. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study. Gynecol. Oncol., 2015, 137(2), 239-244.
11. Kroemer, G.; Galluzzi, L.; Kepp, O.; Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol., 2013, 31, 51-72.
12. Lutsiak, M.E.; Semnani, R.T.; De Pascalis, R.; Kashmiri, S.V.; Schlom, J.; Sabzevari, H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 2005, 105(7), 2862-2868.
13. Rizvi, N.A.; Hellmann, M.D.; Brahmer, J.R.; Juergens, R.A.; Borghaei, H.; Gettinger, S.; Chow, L.Q.; Gerber, D.E.; Laurie, S.A.; Goldman, J.W.; Shepherd, F.A.; Chen, A.C.; Shen, Y.; Nathan, F.E.; Harbison, C.T.; Antonia, S. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol., 2016, 34(25), 2969-2979.
14. Weiner, G.J. Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer, 2015, 15(6), 361-370.
15. Uchida, J.; Hamaguchi, Y.; Oliver, J.A.; Ravetch, J.V.; Poe, J.C.; Haas, K.M.; Tedder, T.F. The innate mononuclear phagocyte network depletes B lymphocytes through Fc re-ceptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med., 2004, 199(12), 1659-1669.
16. Abulayha, A.; Bredan, A.; El Enshasy, H.; Daniels, I. Rituximab: modes of action, remaining dispute and future perspective. Future Oncol., 2014, 10(15), 2481-2492.
17. Scott, A.M.; Wolchok, J.D.; Old, L.J. Antibody therapy of cancer. Nat. Rev. Cancer, 2012, 12(4), 278-287.
18. Curti, B.D.; Kovacsovics-Bankowski, M.; Morris, N.; Walker, E.; Chisholm, L.; Floyd, K.; Walker, J.; Gonzalez, I.; Meeuwsen, T.; Fox, B.A.; Moudgil, T.; Miller, W.; Haley, D.; Coffey, T.; Fisher, B.; Delanty-Miller, L.; Rymar-chyk, N.; Kelly, T.; Crocenzi, T.; Bernstein, E.; Sanborn, R.; Urba, W.J.; Weinberg, A.D. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res., 2013, 73(24), 7189-7198.
19. Gough, M.J.; Ruby, C.E.; Redmond, W.L.; Dhungel, B.; Brown, A.; Weinberg, A.D. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res., 2008, 68(13), 5206-5215.
20. Law, C-L.; Grewal, I.S. Therapeutic interventions targeting CD40L (CD154) and CD40: The opportunities and chal-chal- lenges. In: Therapeutic Targets of the TNF Superfamily; Springer, 2009, pp. 8-36. lenges.
21. Tong, A.W.; Seamour, B.; Chen, J.; Su, D.; Ordonez, G.; Frase, L.; Netto, G.; Stone, M.J. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leuk. Lymphoma, 2000, 36(5-6), 543-558.
22. Johnson, P.; Challis, R.; Chowdhury, F.; Gao, Y.; Harvey, M.; Geldart, T.; Kerr, P.; Chan, C.; Smith, A.; Steven, N.; Edwards, C.; Ashton-Key, M.; Hodges, E.; Tutt, A.; Ottensmeier, C.; Glennie, M.; Williams, A. Clinical and biological effects of an agonist anti-CD40 antibody: A cancer research UK phase I study. Clin. Cancer Res., 2015, 21(6), 1321-1328.
23. Nowak, A.K.; Cook, A.M.; McDonnell, A.M.; Millward, M.J.; Creaney, J.; Francis, R.J.; Hasani, A.; Segal, A.; Musk, A.W.; Turlach, B.A.; McCoy, M.J.; Robinson, B.W.; Lake, R.A. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann. Oncol., 2015, 26(12), 2483-2490.
24. Rüter, J.; Antonia, S.J.; Burris, H.A.; Huhn, R.D.; Vonder-heide, R.H. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol. Ther., 2010, 10(10), 983-993.
25. Furman, R.R.; Forero-Torres, A.; Shustov, A.; Drachman, J.G. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma, 2010, 51(2), 228-235.
26. Hussein, M.; Berenson, J.R.; Niesvizky, R.; Munshi, N.; Matous, J.; Sobecks, R.; Harrop, K.; Drachman, J.G.; Whiting, N. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica, 2010, 95(5), 845-848.
27. Chan, C.J.; Martinet, L.; Gilfillan, S.; Souza-Fonseca-Guimaraes, F.; Chow, M.T.; Town, L.; Ritchie, D.S.; Colonna, M.; Andrews, D.M.; Smyth, M.J. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol., 2014, 15(5), 431-438.
28. Blake, S.J.; Stannard, K.; Liu, J.; Allen, S.; Yong, M.C.; Mittal, D.; Aguilera, A.R.; Miles, J.J.; Lutzky, V.P.; de Andrade, L.F.; Martinet, L.; Colonna, M.; Takeda, K.; Kühnel, F.; Gurlevik, E.; Bernhardt, G.; Teng, M.W.; Smyth, M.J. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov., 2016, 6(4), 446-459.
29. Emens, L.A.; Middleton, G. The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol. Res., 2015, 3(5), 436-443.
30. Casares, N.; Pequignot, M.O.; Tesniere, A.; Ghiringhelli, F.; Roux, S.; Chaput, N.; Schmitt, E.; Hamai, A.; Hervas-Stubbs, S.; Obeid, M.; Coutant, F.; Métivier, D.; Pichard, E.; Aucouturier, P.; Pierron, G.; Garrido, C.; Zitvogel, L.; Kroemer, G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med., 2005, 202(12), 1691-1701.
31. Lesterhuis, W.J.; de Vries, I.J.; Aarntzen, E.A.; de Boer, A.; Scharenborg, N.M.; van de Rakt, M.; van Spronsen, D.J.; Preijers, F.W.; Figdor, C.G.; Adema, G.J.; Punt, C.J. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br. J. Cancer, 2010, 103(9), 1415-1421.
32. Ramakrishnan, R.; Assudani, D.; Nagaraj, S.; Hunter, T.; Cho, H-I.; Antonia, S.; Altiok, S.; Celis, E.; Gabrilovich, D.I. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest., 2010, 120(4), 1111-1124.
33. Kaneno, R.; Shurin, G.V.; Kaneno, F.M.; Naiditch, H.; Luo, J.; Shurin, M.R. Chemotherapeutic agents in low noncyto-toxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol. (Dordr.), 2011, 34(2), 97-106.
34. Vincent, J.; Mignot, G.; Chalmin, F.; Ladoire, S.; Bruchard, M.; Chevriaux, A.; Martin, F.; Apetoh, L.; Rébé, C.; Ghiringhelli, F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res., 2010, 70(8), 3052-3061.
35. Spisek, R.; Charalambous, A.; Mazumder, A.; Vesole, D.H.; Jagannath, S.; Dhodapkar, M.V. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood, 2007, 109(11), 4839-4845.
36. Correale, P.; Botta, C.; Cusi, M.G.; Del Vecchio, M.T.; De Santi, M.M.; Gori Savellini, G.; Bestoso, E.; Apollinari, S.; Mannucci, S.; Marra, M.; Abbruzzese, A.; Aquino, A.; Tur-riziani, M.; Bonmassar, L.; Caraglia, M.; Tagliaferri, P. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int. J. Cancer, 2012, 130(7), 1577-1589.
37. Yang, S.; Haluska, F.G. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme-and Fas-mediated pathways. J. Immunol., 2004, 172(7), 4599-4608.
38. Stumm, S.; Meyer, A.; Lindner, M.; Bastert, G.; Wallwie-ner, D.; Gückel, B. Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor. Oncology, 2004, 66(2), 101-111.
39. Rettig, L.; Seidenberg, S.; Parvanova, I.; Samaras, P.; Curi-oni, A.; Knuth, A.; Pascolo, S. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int. J. Cancer, 2011, 129(4), 832-838.
40. Bauer, C.; Sterzik, A.; Bauernfeind, F.; Duewell, P.; Conrad, C.; Kiefl, R.; Endres, S.; Eigler, A.; Schnurr, M.; Dauer, M. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model. Cancer Immunol. Immunother., 2014, 63(4), 321-333.
41. Shen, Z.T.; Wu, X.H.; Wang, L.; Li, B.; Zhu, X.X. Effects of gemcitabine on radiosensitization, apoptosis, and Bcl-2 and Bax protein expression in human pancreatic cancer xenografts in nude mice. Genet. Mol. Res., 2015, 14(4), 15587-15596.
42. Soeda, A.; Morita-Hoshi, Y.; Makiyama, H.; Morizane, C.; Ueno, H.; Ikeda, M.; Okusaka, T.; Yamagata, S.; Takahashi, N.; Hyodo, I.; Takaue, Y.; Heike, Y. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn. J. Clin. Oncol., 2009, 39(12), 797-806.
43. Vereecque, R.; Saudemont, A.; Quesnel, B. Cytosine arabi-noside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia, 2004, 18(7), 1223-1230.
44. Sistigu, A.; Yamazaki, T.; Vacchelli, E.; Chaba, K.; Enot, D.P.; Adam, J.; Vitale, I.; Goubar, A.; Baracco, E.E.; Remédios, C.; Fend, L.; Hannani, D.; Aymeric, L.; Ma, Y.; Niso-Santano, M.; Kepp, O.; Schultze, J.L.; Tüting, T.; Belardelli, F.; Bracci, L.; La Sorsa, V.; Ziccheddu, G.; Ses-tili, P.; Urbani, F.; Delorenzi, M.; Lacroix-Triki, M.; Quid-ville, V.; Conforti, R.; Spano, J.P.; Pusztai, L.; Poirier-Colame, V.; Delaloge, S.; Penault-Llorca, F.; Ladoire, S.; Arnould, L.; Cyrta, J.; Dessoliers, M.C.; Eggermont, A.; Bianchi, M.E.; Pittet, M.; Engblom, C.; Pfirschke, C.; Préville, X.; Uzè, G.; Schreiber, R.D.; Chow, M.T.; Smyth, M.J.; Proietti, E.; André, F.; Kroemer, G.; Zitvogel, L. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med., 2014, 20(11), 1301-1309.
45. Ghebeh, H.; Lehe, C.; Barhoush, E.; Al-Romaih, K.; Tul-bah, A.; Al-Alwan, M.; Hendrayani, S-F.; Manogaran, P.; Alaiya, A.; Al-Tweigeri, T.; Aboussekhra, A.; Dermime, S. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: Role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res., 2010, 12(4), R48.
46. Liu, N.; Zheng, Y.; Zhu, Y.; Xiong, S.; Chu, Y. Selective impairment of CD4+CD25+Foxp3+ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis. Int. Immunopharmacol., 2011, 11(2), 212-219.
47. Luznik, L.; O’Donnell, P.V.; Symons, H.J.; Chen, A.R.; Leffell, M.S.; Zahurak, M.; Gooley, T.A.; Piantadosi, S.; Kaup, M.; Ambinder, R.F.; Huff, C.A.; Matsui, W.; Bo-laños-Meade, J.; Borrello, I.; Powell, J.D.; Harrington, E.; Warnock, S.; Flowers, M.; Brodsky, R.A.; Sandmaier, B.M.; Storb, R.F.; Jones, R.J.; Fuchs, E.J. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant., 2008, 14(6), 641-650.
48. van der Most, R.G.; Currie, A.J.; Cleaver, A.L.; Salmons, J.; Nowak, A.K.; Mahendran, S.; Larma, I.; Prosser, A.; Robinson, B.W.; Smyth, M.J.; Scalzo, A.A.; Degli-Esposti, M.A.; Lake, R.A. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One, 2009, 4(9), e6982.
49. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol., 2002, 3(11), 991-998.
50. Dengel, L.T.; Norrod, A.G.; Gregory, B.L.; Clancy-Thompson, E.; Burdick, M.D.; Strieter, R.M.; Slingluff, C.L., Jr.; Mullins, D.W. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J. Immunother. (Hagerstown, Md.: 1997), 2010, 33(9), 965-974.
51. Hanke, N.; Alizadeh, D.; Katsanis, E.; Larmonier, N. Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy Crit. Rev. Immunol., 2013, 33(1), 1-21.
52. Koebel, C.M.; Vermi, W.; Swann, J.B.; Zerafa, N.; Rodig, S.J.; Old, L.J.; Smyth, M.J.; Schreiber, R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 2007, 450(7171), 903-907.
53. Quezada, S.A.; Simpson, T.R.; Peggs, K.S.; Merghoub, T.; Vider, J.; Fan, X.; Blasberg, R.; Yagita, H.; Muranski, P.; Antony, P.A.; Restifo, N.P.; Allison, J.P. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med., 2010, 207(3), 637-650.
54. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W-J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 2012, 366(26), 2455-2465.
55. Daud, A. Current and Emerging Perspectives on Immunotherapy for Melanoma. In: Seminars in oncology; Elsevier, 2015.
56. Huang, Y.; Ma, C.; Zhang, Q.; Ye, J.; Wang, F.; Zhang, Y.; Hunborg, P.; Varvares, M.A.; Hoft, D.F.; Hsueh, E.C. Hsueh, CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. 2015, 6(19), 1762-1748.
57. Baksh, K.; Weber, J. Immune checkpoint protein inhibi-tion for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Seminars in oncology; Elsevier, 2015.
58. Honeychurch, J.; Cheadle, E.J.; Dovedi, S.J.; Illidge, T.M. Immunoregulatory antibodies for the treatment of cancer. Expert Opin. Biol. Ther., 2015, 15(6), 787-801.
59. Sansom, D.M. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology, 2000, 101(2), 169-177.
60. Rudd, C.E.; Taylor, A.; Schneider, H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev., 2009, 229(1), 12-26.
61. Walunas, T.L.; Bakker, C.Y.; Bluestone, J.A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med., 1996, 183(6), 2541-2550.
62. Qureshi, O.S.; Zheng, Y.; Nakamura, K.; Attridge, K.; Manzotti, C.; Schmidt, E.M.; Baker, J.; Jeffery, L.E.; Kaur, S.; Briggs, Z.; Hou, T.Z.; Futter, C.E.; Anderson, G.; Walker, L.S.; Sansom, D.M. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science, 2011, 332(6029), 600-603.
63. Wing, K.; Onishi, Y.; Prieto-Martin, P.; Yamaguchi, T.; Miyara, M.; Fehervari, Z.; Nomura, T.; Sakaguchi, S. CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008, 322(5899), 271-275.
64. Quezada, S.A.; Peggs, K.S.; Curran, M.A.; Allison, J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest., 2006, 116(7), 1935-1945.
65. Simpson, T.R.; Li, F.; Montalvo-Ortiz, W.; Sepulveda, M.A.; Bergerhoff, K.; Arce, F.; Roddie, C.; Henry, J.Y.; Yagita, H.; Wolchok, J.D.; Peggs, K.S.; Ravetch, J.V.; Allison, J.P.; Quezada, S.A. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med., 2013, 210(9), 1695-1710.
66. Sutmuller, R.P.; van Duivenvoorde, L.M.; van Elsas, A.; Schumacher, T.N.; Wildenberg, M.E.; Allison, J.P.; Toes, R.E.; Offringa, R.; Melief, C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med., 2001, 194(6), 823-832.
67. Leach, D.R.; Krummel, M.F.; Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science, 1996, 271(5256), 1734-1736.
68. Grosso, J.F.; Jure-Kunkel, M.N. CTLA-4 blockade in tumor models: An overview of preclinical and translational research. Cancer Immun., 2013, 13(1), 5.
69. Ribas, A.; Kefford, R.; Marshall, M.A.; Punt, C.J.; Haanen, J.B.; Marmol, M.; Garbe, C.; Gogas, H.; Schachter, J.; Linette, G.; Lorigan, P.; Kendra, K.L.; Maio, M.; Trefzer, U.; Smylie, M.; McArthur, G.A.; Dreno, B.; Nathan, P.D.; Mackiewicz, J.; Kirkwood, J.M.; Gomez-Navarro, J.; Huang, B.; Pavlov, D.; Hauschild, A. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol., 2013, 31(5), 616-622.
70. Eggermont, A.M.; Chiarion-Sileni, V.; Grob, J.J.; Dummer, R.; Wolchok, J.D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P.A.; Richards, J.M. Richards. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. in ASCO Annual Meeting Proceedings. 2014
71. Ji, R-R.; Chasalow, S.D.; Wang, L.; Hamid, O.; Schmidt, H.; Cogswell, J.; Alaparthy, S.; Berman, D.; Jure-Kunkel, M.; Siemers, N.O.; Jackson, J.R.; Shahabi, V. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother., 2012, 61(7), 1019-1031.
72. Martens, A.; Wistuba-Hamprecht, K.; Yuan, J.; Postow, M.A.; Wong, P.; Capone, M.; Madonna, G.; Khammari, A.; Schilling, B.; Sucker, A. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin. Cancer Res., 2016, 22(19), 4848-4858.
73. Weber, J.S.; Hamid, O.; Chasalow, S.D.; Wu, D.Y.; Parker, S.M.; Galbraith, S.; Gnjatic, S.; Berman, D. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J. Immunother., 2012, 35(1), 89-97.
74. Bjoern, J.; Juul Nitschke, N.; Iversen, T.Z.; Schmidt, H.; Fode, K.; Svane, I.M. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. OncoImmunology, 2015, 5(4), e1100788.
75. Prieto, P.A.; Yang, J.C.; Sherry, R.M.; Hughes, M.S.; Kammula, U.S.; White, D.E.; Levy, C.L.; Rosenberg, S.A.; Phan, G.Q. CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res., 2012, 18(7), 2039-2047.
76. Bowyer, S.; Prithviraj, P.; Lorigan, P.; Larkin, J.; McArthur, G.; Atkinson, V.; Millward, M.; Khou, M.; Diem, S.; Ramanujam, S.; Kong, B.; Liniker, E.; Guminski, A.; Par-ente, P.; Andrews, M.C.; Parakh, S.; Cebon, J.; Long, G.V.; Carlino, M.S.; Klein, O. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br. J. Cancer, 2016, 114(10), 1084-1089.
77. Ribas, A.; Hodi, F.S.; Callahan, M.; Konto, C.; Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med., 2013, 368(14), 1365-1366.
78. Wolchok, J.D.; Hodi, F.S.; Weber, J.S.; Allison, J.P.; Urba, W.J.; Robert, C.; O’Day, S.J.; Hoos, A.; Humphrey, R.; Berman, D.M.; Lonberg, N.; Korman, A.J. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann. N. Y. Acad. Sci., 2013, 1291(1), 1-13.
79. Weber, J.S.; Kähler, K.C.; Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol., 2012, 30(21), 2691-2697.
80. Yun, S.; Vincelette, N.D.; Green, M.R. Wahner Hen-drickson, A.E.; Abraham, I. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: A systematic re-view and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med., 2016, 5(7), 1481-1491.
81. Lu, J.; Lee-Gabel, L.; Nadeau, M.C.; Ferencz, T.M.; Soefje, S.A. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J. Oncol. Pharm. Pract., 2015, 21(6), 451-467.
82. Freeman, G.J.; Long, A.J.; Iwai, Y.; Bourque, K.; Cher-nova, T.; Nishimura, H.; Fitz, L.J.; Malenkovich, N.; Okazaki, T.; Byrne, M.C.; Horton, H.F.; Fouser, L.; Carter, L.; Ling, V.; Bowman, M.R.; Carreno, B.M.; Collins, M.; Wood, C.R.; Honjo, T. Engagement of the PD-1 immu-noinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 2000, 192(7), 1027-1034.
83. Fife, B.T.; Pauken, K.E.; Eagar, T.N.; Obu, T.; Wu, J.; Tang, Q.; Azuma, M.; Krummel, M.F.; Bluestone, J.A. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol., 2009, 10(11), 1185-1192.
84. Patsoukis, N.; Brown, J.; Petkova, V.; Liu, F.; Li, L.; Bous-siotis, V.A. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci. Signal., 2012, 5(230), ra46-ra46.
85. Parry, R.V.; Chemnitz, J.M.; Frauwirth, K.A.; Lanfranco, A.R.; Braunstein, I.; Kobayashi, S.V.; Linsley, P.S.; Thompson, C.B.; Riley, J.L. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol., 2005, 25(21), 9543-9553.
86. Jiang, Y.; Li, Y.; Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis., 2015, 6(6), e1792.
87. Jin, H-T.; Anderson, A.C.; Tan, W.G.; West, E.E.; Ha, S-J.; Araki, K.; Freeman, G.J.; Kuchroo, V.K.; Ahmed, R. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. USA, 2010, 107(33), 14733-14738.
88. Fourcade, J.; Sun, Z.; Pagliano, O.; Guillaume, P.; Luescher, I.F.; Sander, C.; Kirkwood, J.M.; Olive, D.; Kuchroo, V.; Zarour, H.M. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res., 2012, 72(4), 887-896.
89. Blackburn, S.D.; Shin, H.; Haining, W.N.; Zou, T.; Workman, C.J.; Polley, A.; Betts, M.R.; Freeman, G.J.; Vignali, D.A.; Wherry, E.J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol., 2009, 10(1), 29-37.
90. Ahmadzadeh, M.; Johnson, L.A.; Heemskerk, B.; Wunder-lich, J.R.; Dudley, M.E.; White, D.E.; Rosenberg, S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 2009, 114(8), 1537-1544.
91. Sfanos, K.S.; Bruno, T.C.; Meeker, A.K.; De Marzo, A.M.; Isaacs, W.B.; Drake, C.G. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate, 2009, 69(15), 1694-1703.
92. Muenst, S.; Soysal, S.D.; Gao, F.; Obermann, E.C.; Oertli, D.; Gillanders, W.E. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat., 2013, 139(3), 667-676.
93. Matsuzaki, J.; Gnjatic, S.; Mhawech-Fauceglia, P.; Beck, A.; Miller, A.; Tsuji, T.; Eppolito, C.; Qian, F.; Lele, S.; Shrikant, P.; Old, L.J.; Odunsi, K. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. USA, 2010, 107(17), 7875-7880.
94. Eisele, S.C.R.; David, A. Blocking the PD-1/PD-L1 signaling pathway in malignant glioma: Current and future perspectives. Contemp. Oncol., 2015.
95. Lee, S-K.; Seo, S-H.; Kim, B-S.; Kim, C-D.; Lee, J-H.; Kang, J-S.; Maeng, P.J.; Lim, J-S. IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. J. Dermatol. Sci., 2005, 40(2), 95-103.
96. Barber, D.L.; Wherry, E.J.; Masopust, D.; Zhu, B.; Allison, J.P.; Sharpe, A.H.; Freeman, G.J.; Ahmed, R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 2006, 439(7077), 682-687.
97. Iwai, Y.; Ishida, M.; Tanaka, Y.; Okazaki, T.; Honjo, T.; Minato, N. Involvement of PD-L1 on tumor cells in the es-es- cape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA, 2002, 99(19), 12293-12297. cape
98. Iwai, Y.; Terawaki, S.; Honjo, T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol., 2005, 17(2), 133-144.
99. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med., 2012, 366(26), 2443-2454.
100. Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.; Millenson, M.M.; Cattry, D.; Freeman, G.J.; Rodig, S.J.; Chapuy, B.; Ligon, A.H.; Zhu, L.; Grosso, J.F.; Kim, S.Y.; Timmerman, J.M.; Shipp, M.A.; Armand, P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med., 2015, 372(4), 311-319.
101. Topalian, S.L.; Sznol, M.; McDermott, D.F.; Kluger, H.M.; Carvajal, R.D.; Sharfman, W.H.; Brahmer, J.R.; Lawrence, D.P.; Atkins, M.B.; Powderly, J.D.; Leming, P.D.; Lipson, E.J.; Puzanov, I.; Smith, D.C.; Taube, J.M.; Wigginton, J.M.; Kollia, G.D.; Gupta, A.; Pardoll, D.M.; Sosman, J.A.; Hodi, F.S. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol., 2014, 32(10), 1020-1030.
102. Weber, J.S.; D’Angelo, S.P.; Minor, D.; Hodi, F.S.; Gutz-mer, R.; Neyns, B.; Hoeller, C.; Khushalani, N.I.; Miller, W.H., Jr; Lao, C.D.; Linette, G.P.; Thomas, L.; Lorigan, P.; Grossmann, K.F.; Hassel, J.C.; Maio, M.; Sznol, M.; Ascierto, P.A.; Mohr, P.; Chmielowski, B.; Bryce, A.; Svane, I.M.; Grob, J.J.; Krackhardt, A.M.; Horak, C.; Lambert, A.; Yang, A.S.; Larkin, J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol., 2015, 16(4), 375-384.
103. Brahmer, J.; Reckamp, K.L.; Baas, P.; Crinò, L.; Eberhardt, W.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; Waterhouse, D.; Ready, N.; Gainor, J.; Arén Frontera, O.; Havel, L.; Steins, M.; Garassino, M.C.; Aerts, J.G.; Domine, M.; Paz-Ares, L.; Reck, M.; Baudelet, C.; Harbison, C.T.; Lestini, B.; Spigel, D.R. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med., 2015, 373(2), 123-135.
104. Robert, C.; Long, G.V.; Brady, B.; Dutriaux, C.; Maio, M.; Mortier, L.; Hassel, J.C.; Rutkowski, P.; McNeil, C.; Ka-linka-Warzocha, E.; Savage, K.J.; Hernberg, M.M.; Lebbé, C.; Charles, J.; Mihalcioiu, C.; Chiarion-Sileni, V.; Mauch, C.; Cognetti, F.; Arance, A.; Schmidt, H.; Schadendorf, D.; Gogas, H.; Lundgren-Eriksson, L.; Horak, C.; Sharkey, B.; Waxman, I.M.; Atkinson, V.; Ascierto, P.A. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med., 2015, 372(4), 320-330.
105. Robert, C.; Ribas, A.; Wolchok, J.D.; Hodi, F.S.; Hamid, O.; Kefford, R.; Weber, J.S.; Joshua, A.M.; Hwu, W-J.; Gangadhar, T.C.; Patnaik, A.; Dronca, R.; Zarour, H.; Joseph, R.W.; Boasberg, P.; Chmielowski, B.; Mateus, C.; Postow, M.A.; Gergich, K.; Elassaiss-Schaap, J.; Li, X.N.; Iannone, R.; Ebbinghaus, S.W.; Kang, S.P.; Daud, A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A ran-domised dose-comparison cohort of a phase 1 trial. Lancet, 2014, 384(9948), 1109-1117.
106. Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; Carcereny, E.; Ahn, M.J.; Felip, E.; Lee, J.S.; Hellmann, M.D.; Hamid, O.; Goldman, J.W.; Soria, J.C.; Dolled-Filhart, M.; Rutledge, R.Z.; Zhang, J.; Lunceford, J.K.; Rangwala, R.; Lubiniecki, G.M.; Roach, C.; Emancipator, K.; Gandhi, L. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med., 2015, 372(21), 2018-2028.
107. Daud, A.I.; Hamid, O.; Ribas, A.; Hodi, F.S.; Hwu, W-J.; Kefford, R.; Wolchok, J.; Hersey, P.; Weber, J.S.; Joseph, R. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma (MEL): Correlation of tumor PD-L1 expression with outcome. Cancer Res., 2014, 74(19)(Suppl.), CT104-CT104.
108. Ribas, A.; Puzanov, I.; Dummer, R.; Schadendorf, D.; Hamid, O.; Robert, C.; Hodi, F.S.; Schachter, J.; Pavlick, A.C.; Lewis, K.D.; Cranmer, L.D.; Blank, C.U.; O’Day, S.J.; Ascierto, P.A.; Salama, A.K.; Margolin, K.A.; Loquai, C.; Eigentler, T.K.; Gangadhar, T.C.; Carlino, M.S.; Agar-wala, S.S.; Moschos, S.J.; Sosman, J.A.; Goldinger, S.M.; Shapira-Frommer, R.; Gonzalez, R.; Kirkwood, J.M.; Wolchok, J.D.; Eggermont, A.; Li, X.N.; Zhou, W.; Zernhelt, A.M.; Lis, J.; Ebbinghaus, S.; Kang, S.P.; Daud, A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol., 2015, 16(8), 908-918.
109. Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; Larkin, J.; Lorigan, P.; Neyns, B.; Blank, C.U.; Hamid, O.; Mateus, C.; Shapira-Frommer, R.; Kosh, M.; Zhou, H.; Ibrahim, N.; Ebbinghaus, S.; Ribas, A. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med., 2015, 372(26), 2521-2532.
110. Westin, J.R.; Chu, F.; Zhang, M.; Fayad, L.E.; Kwak, L.W.; Fowler, N.; Romaguera, J.; Hagemeister, F.; Fanale, M.; Samaniego, F.; Feng, L.; Baladandayuthapani, V.; Wang, Z.; Ma, W.; Gao, Y.; Wallace, M.; Vence, L.M.; Radvanyi, L.; Muzzafar, T.; Rotem-Yehudar, R.; Davis, R.E.; Nee-lapu, S.S. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol., 2014, 15(1), 69-77.
111. Berger, R.; Rotem-Yehudar, R.; Slama, G.; Landes, S.; Kneller, A.; Leiba, M.; Koren-Michowitz, M.; Shimoni, A.; Nagler, A. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res., 2008, 14(10), 3044-3051.
112. Armand, P.; Nagler, A.; Weller, E.A.; Devine, S.M.; Avi-gan, D.E.; Chen, Y-B.; Kaminski, M.S.; Holland, H.K.; Winter, J.N.; Mason, J.R.; Fay, J.W.; Rizzieri, D.A.; Hosing, C.M.; Ball, E.D.; Uberti, J.P.; Lazarus, H.M.; Mapara, M.Y.; Gregory, S.A.; Timmerman, J.M.; Andorsky, D.; Or, R.; Waller, E.K.; Rotem-Yehudar, R.; Gordon, L.I. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol., 2013, 31(33), 4199-4206.
113. Fujii, R.; Friedman, E.R.; Richards, J.; Tsang, K.Y.; Heery, C.R.; Schlom, J.; Hodge, J.W. Enhanced killing of chor-doma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget, 2016, 7(23), 33498.
114. Boyerinas, B.; Jochems, C.; Fantini, M.; Heery, C.R.; Gulley, J.L.; Tsang, K.Y.; Schlom, J. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol. Res., 2015, 3(10), 1148-1157.
115. Heery, C.R.; O’Sullivan Coyne, G.H.; Madan, R.A.; Schlom, J.; von Heydebreck, A.; Cuillerot, J-M.; Sabzevari, H.; Gulley, J.L. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. in ASCO Annual Meeting Proceedings. 2014.
116. Disis, M.L.; Patel, M.R.; Pant, S.; Infante, J.R.; Lockhart, A.C.; Kelly, K.; Beck, J.T.; Gordon, M.S.; Weiss, G.J.; Ejadi, S. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. in ASCO Annual Meeting Proceedings. 2015.
117. Kaufman, H.L.; Russell, J.; Hamid, O.; Bhatia, S.; Terhey-den, P.; D’Angelo, S.P.; Shih, K.C.; Lebbé, C.; Linette, G.P.; Milella, M.; Brownell, I.; Lewis, K.D.; Lorch, J.H.; Chin, K.; Mahnke, L.; von Heydebreck, A.; Cuillerot, J.M.; Nghiem, P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol., 2016, 17(10), 1374-1385.
118. Smuga-Otto, K. Nods for atezolizumab and nivolumab from FDA. Cancer Discov., 2016, 6(8), 811.
119. McDermott, D.F.; Sosman, J.A.; Sznol, M.; Massard, C.; Gordon, M.S.; Hamid, O.; Powderly, J.D.; Infante, J.R.; Fassò, M.; Wang, Y.V.; Zou, W.; Hegde, P.S.; Fine, G.D.; Powles, T. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity, and immune correlates from a phase ia study. J. Clin. Oncol., 2016, 34(8), 833-842.
120. Rosenberg, J.E.; Hoffman-Censits, J.; Powles, T.; van der Heijden, M.S.; Balar, A.V.; Necchi, A.; Dawson, N.; O’Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; Srinivas, S.; Retz, M.M.; Grivas, P.; Joseph, R.W.; Galsky, M.D.; Fleming, M.T.; Petrylak, D.P.; Perez-Gracia, J.L.; Burris, H.A.; Castellano, D.; Canil, C.; Bellmunt, J.; Bajorin, D.; Nickles, D.; Bourgon, R.; Frampton, G.M.; Cui, N.; Maria-thasan, S.; Abidoye, O.; Fine, G.D.; Dreicer, R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet, 2016, 387(10031), 1909-1920.
121. Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C.; Braiteh, F.; Waterkamp, D.; He, P.; Zou, W.; Chen, D.S.; Yi, J.; Sandler, A.; Rittmeyer, A. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet, 2016, 387(10030), 1837-1846.
122. Massard, C.; Gordon, M.S.; Sharma, S.; Rafii, S.; Wain-berg, Z.A.; Luke, J.; Curiel, T.J.; Colon-Otero, G.; Hamid, O.; Sanborn, R.E.; O’Donnell, P.H.; Drakaki, A.; Tan, W.; Kurland, J.F.; Rebelatto, M.C.; Jin, X.; Blake-Haskins, J.A.; Gupta, A.; Segal, N.H. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol., 2016, 34(26), 3119-3125.
123. Planchard, D.; Yokoi, T.; McCleod, M.J.; Fischer, J.R.; Kim, Y.-C.; Ballas, M.; Shi, K.; Soria, J.-C. A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: Rationale and protocol design of the ARCTIC study. Clin. lung cancer, 2016, 17(3), 232-236.
124. Wilcox, R.A.; Flies, D.B.; Zhu, G.; Johnson, A.J.; Tamada, K.; Chapoval, A.I.; Strome, S.E.; Pease, L.R.; Chen, L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest., 2002, 109(5), 651-659.
125. Shuford, W.W.; Klussman, K.; Tritchler, D.D.; Loo, D.T.; Chalupny, J.; Siadak, A.W.; Brown, T.J.; Emswiler, J.; Raecho, H.; Larsen, C.P.; Pearson, T.C.; Ledbetter, J.A.; Aruffo, A.; Mittler, R.S. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med., 1997, 186(1), 47-55.
126. Kohrt, H.E.; Houot, R.; Goldstein, M.J.; Weiskopf, K.; Alizadeh, A.A.; Brody, J.; Müller, A.; Pachynski, R.; Czerwinski, D.; Coutre, S.; Chao, M.P.; Chen, L.; Tedder, T.F.; Levy, R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood, 2011, 117(8), 2423-2432.
127. Melero, I.; Shuford, W.W.; Newby, S.A.; Aruffo, A.; Ledbetter, J.A.; Hellström, K.E.; Mittler, R.S.; Chen, L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med., 1997, 3(6), 682-685.
128. Kim, J.A.; Averbook, B.J.; Chambers, K.; Rothchild, K.; Kjaergaard, J.; Papay, R.; Shu, S. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res., 2001, 61(5), 2031-2037.
129. Kohrt, H.E.; Houot, R.; Weiskopf, K.; Goldstein, M.J.; Scheeren, F.; Czerwinski, D.; Colevas, A.D.; Weng, W-K.; Clarke, M.F.; Carlson, R.W.; Stockdale, F.E.; Mollick, J.A.; Chen, L.; Levy, R. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest., 2012, 122(3), 1066-1075.
130. Kohrt, H.E.; Colevas, A.D.; Houot, R.; Weiskopf, K.; Goldstein, M.J.; Lund, P.; Mueller, A.; Sagiv-Barfi, I.; Mara-belle, A.; Lira, R.; Troutner, E.; Richards, L.; Rajapaska, A.; Hebb, J.; Chester, C.; Waller, E.; Ostashko, A.; Weng, W.K.; Chen, L.; Czerwinski, D.; Fu, Y.X.; Sunwoo, J.; Levy, R. Targeting CD137 enhances the efficacy of cetuximab. J. Clin. Invest., 2014, 124(6), 2668-2682.
131. Zhu, Y.; Zhu, G.; Luo, L.; Flies, A.S.; Chen, L. CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood, 2007, 109(11), 4882-4889.
132. Narazaki, H.; Zhu, Y.; Luo, L.; Zhu, G.; Chen, L. CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood, 2010, 115(10), 1941-1948.
133. Dubrot, J.; Milheiro, F.; Alfaro, C.; Palazón, A.; Martinez-Forero, I.; Perez-Gracia, J.L.; Morales-Kastresana, A.; Ro-mero-Trevejo, J.L.; Ochoa, M.C.; Hervás-Stubbs, S.; Prieto, J.; Jure-Kunkel, M.; Chen, L.; Melero, I. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol. Immunother., 2010, 59(8), 1223-1233.
134. Sznol, M.; Hodi, F.; Margolin, K.; McDermott, D.; Ernstoff, M.; Kirkwood, J.; Wojtaszek, C.; Feltquate, D.; Logan, T. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). in ASCO Annual Meeting Proceedings. 2008.
135. Segal, N.H.; Gopal, A.K.; Bhatia, S.; Kohrt, H.E.; Levy, R.; Pishvaian, M.J.; Houot, R.; Bartlett, N.; Nghiem, P.; Kronenberg, S.A. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. in ASCO Annual Meeting Proceedings. 2014.
136. Chen, S-J.; Jiaang, W-T. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV,-II, 8/9 and fibroblast activation protein. Curr. Top. Med. Chem., 2011, 11(12), 1447-1463.
137. De Meester, I.; Korom, S.; Van Damme, J.; Scharpé, S. CD26, let it cut or cut it down. Immunol. Today, 1999, 20(8), 367-375.
138. Casrouge, A.; Decalf, J.; Ahloulay, M.; Lababidi, C.; Mansour, H.; Vallet-Pichard, A.; Mallet, V.; Mottez, E.; Mapes, J.; Fontanet, A.; Pol, S.; Albert, M.L. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest., 2011, 121(1), 308-317.
139. Lambeir, A-M.; Proost, P.; Durinx, C.; Bal, G.; Senten, K.; Augustyns, K.; Scharpé, S.; Van Damme, J.; De Meester, I. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem., 2001, 276(32), 29839-29845.
140. Rainczuk, A.; Rao, J.; Gathercole, J.; Stephens, A.N. The emerging role of CXC chemokines in epithelial ovarian cancer. Reproduction, 2012, 144(3), 303-317.
141. Kieffer, T.J.; McIntosh, C.H.; Pederson, R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 1995, 136(8), 3585-3596.
142. Balkan, B.; Kwasnik, L.; Miserendino, R.; Holst, J.J.; Li, X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabe-tologia, 1999, 42(11), 1324-1331.
143. Deacon, C.F.; Danielsen, P.; Klarskov, L.; Olesen, M.; Holst, J.J. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes, 2001, 50(7), 1588-1597.
144. Vincent, S.H.; Reed, J.R.; Bergman, A.J.; Elmore, C.S.; Zhu, B.; Xu, S.; Ebel, D.; Larson, P.; Zeng, W.; Chen, L.; Dilzer, S.; Lasseter, K.; Gottesdiener, K.; Wagner, J.A.; Herman, G.A. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab. Dispos., 2007, 35(4), 533-538.
145. Augeri, D.J.; Robl, J.A.; Betebenner, D.A.; Magnin, D.R.; Khanna, A.; Robertson, J.G.; Wang, A.; Simpkins, L.M.; Taunk, P.; Huang, Q.; Han, S.P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G.E.; Egan, D.M.; Marcinkeviciene, J.; Chang, S.Y.; Biller, S.A.; Kirby, M.S.; Parker, R.A.; Hamann, L.G. Discovery and preclinical profile of Saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48(15), 5025-5037.
146. Blech, S.; Ludwig-Schwellinger, E.; Gräfe-Mody, E.U.; Withopf, B.; Wagner, K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab. Dispos., 2010, 38(4), 667-678.
147. Feng, J.; Zhang, Z.; Wallace, M.B.; Stafford, J.A.; Kaldor, S.W.; Kassel, D.B.; Navre, M.; Shi, L.; Skene, R.J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D.R.; Gwaltney, S.L., II Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem., 2007, 50(10), 2297-2300.
148. He, H.; Tran, P.; Yin, H.; Smith, H.; Batard, Y.; Wang, L.; Einolf, H.; Gu, H.; Mangold, J.B.; Fischer, V.; Howard, D. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab. Dispos., 2009, 37(3), 536-544.
149. Clancy-Thompson, E.; Perekslis, T.J.; Croteau, W.; Alexander, M.P.; Chabanet, T.B.; Turk, M.J.; Huang, Y.H.; Mullins, D.W. Melanoma induces, and adenosine suppresses, CXCR3-cognate chemokine production and T-cell infil-tration of lungs bearing metastatic-like disease. Cancer Immunol. Res., 2015, 3(8), 956-967.
150. Chew, V.; Chen, J.; Lee, D.; Loh, E.; Lee, J.; Lim, K.H.; Weber, A.; Slankamenac, K.; Poon, R.T.; Yang, H. Chemokine-driven lymphocyte infiltration: An early intra-tumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut, 2012, 61(3), 427-438.
151. Pagès, F.; Galon, J.; Dieu-Nosjean, M.C.; Tartour, E.; Sautès-Fridman, C.; Fridman, W.H. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene, 2010, 29(8), 1093-1102.
152. Rainczuk, A.; Rao, J.R.; Gathercole, J.L.; Fairweather, N.J.; Chu, S.; Masadah, R.; Jobling, T.W.; Deb-Choudhury, S.; Dyer, J.; Stephens, A.N. Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours. Int. J. Cancer, 2014, 134(3), 530-541.
153. Proost, P.; Schutyser, E.; Menten, P.; Struyf, S.; Wuyts, A.; Opdenakker, G.; Detheux, M.; Parmentier, M.; Durinx, C.; Lambeir, A-M.; Neyts, J.; Liekens, S.; Maudgal, P.C.; Bil-liau, A.; Van Damme, J. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood, 2001, 98(13), 3554-3561.
154. Pethiyagoda, C.L.; Welch, D.R.; Fleming, T.P. Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin. Exp. Metastasis, 2000, 18(5), 391-400.
155. Kajiyama, H.; Kikkawa, F.; Khin, E.; Shibata, K.; Ino, K.; Mizutani, S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res., 2003, 63(9), 2278-2283.
156. Kajiyama, H.; Shibata, K.; Terauchi, M.; Ino, K.; Nawa, A.; Kikkawa, F. Involvement of DPPIV/CD26 in epithelial morphology and suppressed invasive ability in ovarian carcinoma cells. Ann. N. Y. Acad. Sci., 2006, 1086(1), 233-240.
157. Beckenkamp, A.; Willig, J.B.; Santana, D.B.; Nascimento, J.; Paccez, J.D.; Zerbini, L.F.; Bruno, A.N.; Pilger, D.A.; Wink, M.R.; Buffon, A. Differential expression and enzymatic activity of DPPIV/CD26 affects migration ability of cervical carcinoma cells. PLoS One, 2015, 10(7), e0134305.
158. Arscott, W.T.; LaBauve, A.E.; May, V.; Wesley, U.V. Suppression of neuroblastoma growth by dipeptidyl peptidase IV: Relevance of chemokine regulation and caspase activation. Oncogene, 2009, 28(4), 479-491.
159. Busek, P.; Stremenova, J.; Sromova, L.; Hilser, M.; Balaz-iova, E.; Kosek, D.; Trylcova, J.; Strnad, H.; Krepela, E.; Sedo, A. Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity. Int. J. Biochem. Cell Biol., 2012, 44(5), 738-747.
160. Sun, Y-X.; Pedersen, E.A.; Shiozawa, Y.; Havens, A.M.; Jung, Y.; Wang, J.; Pienta, K.J.; Taichman, R.S. CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin. Exp. Metastasis, 2008, 25(7), 765-776.
161. Barreira da Silva, R.; Laird, M.E.; Yatim, N.; Fiette, L.; Ingersoll, M.A.; Albert, M.L. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat. Immunol., 2015, 16(8), 850-858.
162. Zhang, M.; Xu, L.; Wang, X.; Sun, B.; Ding, J. Expression levels of seprase/FAPα and DPPIV/CD26 in epithelial ovarian carcinoma. Oncol. Lett., 2015, 10(1), 34-42.
163. Jang, J-H.; Baerts, L.; Waumans, Y.; De Meester, I.; Yamada, Y.; Limani, P.; Gil-Bazo, I.; Weder, W.; Jungraith-mayr, W. Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice. Clin. Exp. Metastasis, 2015, 32(7), 677-687.
164. Choi, H.J.; Kim, J.Y.; Lim, S.C.; Kim, G.; Yun, H.J.; Choi, H.S. Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression. Br. J. Pharmacol., 2015, 172(21), 5096-5109.
165. Kajiyama, H.; Kikkawa, F.; Maeda, O.; Suzuki, T.; Ino, K.; Mizutani, S. Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology, 2002, 63(2), 158-165.
166. Wilson, M.J.; Haller, R.; Li, S.Y.; Slaton, J.W.; Sinha, A.A.; Wasserman, N.F. Elevation of dipeptidylpeptidase iv activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: Possible prostate cancer disease marker. J. Urol., 2005, 174(3), 1124-1128.
167. Kajiyama, H.; Shibata, K.; Ino, K.; Mizutani, S.; Nawa, A.; Kikkawa, F. The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitiv-ity to paclitaxel in epithelial ovarian carcinoma cells. Cancer Sci., 2010, 101(2), 347-354.
168. Larrinaga, G.; Perez, I.; Sanz, B.; Beitia, M.; Errarte, P.; Fernández, A.; Blanco, L.; Etxezarraga, M.C.; Gil, J.; López, J.I. Dipeptidyl-peptidase IV activity is correlated with colorectal cancer prognosis. PLoS One, 2015, 10(3), e0119436.
169. De Chiara, L.; Rodríguez-Piñeiro, A.M.; Cordero, O.J.; Vázquez-Tuñas, L.; Ayude, D.; Rodríguez-Berrocal, F.J.; de la Cadena, M.P. Postoperative serum levels of sCD26 for surveillance in colorectal cancer patients. PLoS One, 2014, 9(9), e107470.
170. Huang, S.M.; Zhao, H.; Lee, J.I.; Reynolds, K.; Zhang, L.; Temple, R.; Lesko, L.J. Therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Ther., 2010, 87(4), 497-503.
171. Reck, M.; Bondarenko, I.; Luft, A.; Serwatowski, P.; Barlesi, F.; Chacko, R.; Sebastian, M.; Lu, H.; Cuillerot, J-M.; Lynch, T.J. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol., 2013, 24(1), 75-83.
172. Tesniere, A.; Apetoh, L.; Ghiringhelli, F.; Joza, N.; Panare-takis, T.; Kepp, O.; Schlemmer, F.; Zitvogel, L.; Kroemer, G. Immunogenic cancer cell death: A key-lock paradigm. Curr. Opin. Immunol., 2008, 20(5), 504-511.
173. Merritt, R.E.; Mahtabifard, A.; Yamada, R.E.; Crystal, R.G.; Korst, R.J. Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer. J. Thorac. Cardiovasc. Surg., 2003, 126(5), 1609-1617.
174. Masters, G.; Barreto, L.; Girit, E.; Jure-Kunkel, M. Antitumor activity of cytotoxic T-lymphocyte antigen-4 blockade alone or combined with paclitaxel, etoposide, or gemcitabine in murine models in Journal of Immunotherapy. 2009. Lippincott Williams & Wilkins 530 Walnut St, Philadelphia, PA 19106-3621 USA.
175. Weber, J.; Hamid, O.; Amin, A.; O’Day, S.; Masson, E.; Goldberg, S.M.; Williams, D.; Parker, S.M.; Chasalow, S.D.; Alaparthy, S.; Wolchok, J.D. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun., 2013, 13(2), 7.
176. Lynch, T.J.; Bondarenko, I.; Luft, A.; Serwatowski, P.; Barlesi, F.; Chacko, R.; Sebastian, M.; Neal, J.; Lu, H.; Cuillerot, J-M.; Reck, M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol., 2012, 30(17), 2046-2054.
177. Braly, P.; Nicodemus, C.F.; Chu, C.; Collins, Y.; Edwards, R.; Gordon, A.; McGuire, W.; Schoonmaker, C.; Whiteside, T.; Smith, L.M.; Method, M. The Immune adjuvant properties of front-line carboplatin-paclitaxel: A randomized phase 2 study of alternative schedules of intravenous orego-vomab chemoimmunotherapy in advanced ovarian cancer. J. Immunother., 2009, 32(1), 54-65.
178. Hervieu, A.; Rébé, C.; Végran, F.; Chalmin, F.; Bruchard, M.; Vabres, P.; Apetoh, L.; Ghiringhelli, F.; Mignot, G. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J. Invest. Dermatol., 2013, 133(2), 499-508.
179. Hersh, E.M.; O’Day, S.J.; Powderly, J.; Khan, K.D.; Pavlick, A.C.; Cranmer, L.D.; Samlowski, W.E.; Nichol, G.M.; Yellin, M.J.; Weber, J.S. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest. New Drugs, 2011, 29(3), 489-498.
180. Wolchok, J.D.; Neyns, B.; Linette, G.; Negrier, S.; Lutzky, J.; Thomas, L.; Waterfield, W.; Schadendorf, D.; Smylie, M.; Guthrie, T., Jr; Grob, J.J.; Chesney, J.; Chin, K.; Chen, K.; Hoos, A.; O’Day, S.J.; Lebbé, C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol., 2010, 11(2), 155-164.
181. Wolchok, J.D.; Hoos, A.; O’Day, S.; Weber, J.S.; Hamid, O.; Lebbé, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G.; Humphrey, R.; Hodi, F.S. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res., 2009, 15(23), 7412-7420.
182. Maio, M.; Grob, J.-J.; Aamdal, S.; Bondarenko, I.; Robert, C.; Thomas, L.; Garbe, C.; Chiarion-Sileni, V.; Testori, A.; Chen, T.-T. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol., 2015, 33(10), 1191-1196.
183. Aglietta, M.; Barone, C.; Sawyer, M.B.; Moore, M.J.; Miller, W.H., Jr; Bagalà, C.; Colombi, F.; Cagnazzo, C.; Gioeni, L.; Wang, E.; Huang, B.; Fly, K.D.; Leone, F. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Ann. Oncol., 2014, 25(9), 1750-1755.
184. Plate, J.M.; Plate, A.E.; Shott, S.; Bograd, S.; Harris, J.E. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol. Immunother., 2005, 54(9), 915-925.
185. Suzuki, E.; Kapoor, V.; Jassar, A.S.; Kaiser, L.R.; Albelda, S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res., 2005, 11(18), 6713-6721.
186. Pfirschke, C.; Engblom, C.; Rickelt, S.; Cortez-Retamozo, V.; Garris, C.; Pucci, F.; Yamazaki, T.; Poirier-Colame, V.; Newton, A.; Redouane, Y.; Lin, Y.J.; Wojtkiewicz, G.; Iwamoto, Y.; Mino-Kenudson, M.; Huynh, T.G.; Hynes, R.O.; Freeman, G.J.; Kroemer, G.; Zitvogel, L.; Weissleder, R.; Pittet, M.J. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity, 2016, 44(2), 343-354.
187. Rios-Doria, J.; Durham, N.; Wetzel, L.; Rothstein, R.; Che-sebrough, J.; Holoweckyj, N.; Zhao, W.; Leow, C.C.; Hollingsworth, R. Doxil synergizes with cancer immuno-therapies to enhance antitumor responses in syngeneic mouse models. Neoplasia, 2015, 17(8), 661-670.
188. Jure-Kunkel, M.; Masters, G.; Girit, E.; Dito, G.; Lee, F.; Hunt, J.T.; Humphrey, R. Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol. Immunother., 2013, 62(9), 1533-1545.
189. Lesterhuis, W.J.; Salmons, J.; Nowak, A.K.; Rozali, E.N.; Khong, A.; Dick, I.M.; Harken, J.A.; Robinson, B.W.; Lake, R.A. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One, 2013, 8(4), e61895.
190. Wu, L.; Yun, Z.; Tagawa, T.; Rey-McIntyre, K.; de Perrot, M. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol. Cancer Ther., 2012, 11(8), 1809-1819.
191. Meng, X.; Huang, Z.; Teng, F.; Xing, L.; Yu, J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat. Rev., 2015, 41(10), 868-876.
192. Bernicker, E. Next-generation sequencing and immunotherapy biomarkers: A medical oncology perspective. Arch. Pathol. Lab. Med., 2016, 140(3), 245-248.
193. Kefford, R.; Ribas, A.; Hamid, O.; Robert, C.; Daud, A.; Wolchok, J.D.; Joshua, A.M.; Hodi, F.S.; Gangadhar, T.C.; Hersey, P. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. Am. Soc. Clin. Oncol., 2014, 32, 3005.
194. Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; Barlesi, F.; Kohlhäufl, M.; Arrieta, O.; Burgio, M.A.; Fayette, J.; Lena, H.; Poddubskaya, E.; Gerber, D.E.; Gettinger, S.N.; Rudin, C.M.; Rizvi, N.; Crinò, L.; Blumen-schein, G.R., Jr; Antonia, S.J.; Dorange, C.; Harbison, C.T.; Graf Finckenstein, F.; Brahmer, J.R. Nivolumab versus docetaxel in advanced nonsqua-mous non-small-cell lung cancer. N. Engl. J. Med., 2015, 373(17), 1627-1639.
195. Carbognin, L.; Pilotto, S.; Milella, M.; Vaccaro, V.; Brunelli, M.; Caliò, A.; Cuppone, F.; Sperduti, I.; Giannarelli, D.; Chilosi, M.; Bronte, V.; Scarpa, A.; Bria, E.; Tortora, G. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 2015, 10(6), e0130142.
196. Rahimian, S.; Fransen, M.F.; Kleinovink, J.W.; Amidi, M.; Ossendorp, F.; Hennink, W.E. Hennink, Polymeric mi-croparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. Biomaterials, 2015, 61, 33-40.
197. Chen, R.; Wang, F.; Zhang, H.; Chen, B. Brentuximab ve-dotin for treatment of relapsed or refractory malignant lymphoma: Results of a systematic review and meta-analysis of prospective studies. Drug Des. Devel. Ther., 2015, 9, 2277.
198. Mestas, J.; Hughes, C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol., 2004, 172(5), 2731-2738.
199. Farrar, J.D.; Smith, J.D.; Murphy, T.L.; Leung, S.; Stark, G.R.; Murphy, K.M. Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nat. Immunol., 2000, 1(1), 65-69.
200. Lenschow, D.J.; Walunas, T.L.; Bluestone, J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol., 1996, 14(1), 233-258.
201. Cook, A.M.; Lesterhuis, W.J.; Nowak, A.K.; Lake, R.A.; Cook, A.M.; Lesterhuis, W.J.; Nowak, A.K.; Lake, R.A. Chemotherapy and immunotherapy: Mapping the road ahead. Curr. Opin. Immunol., 2016, 39, 23-29.
202. Ciampricotti, M.; Hau, C-S.; Doornebal, C.W.; Jonkers, J.; de Visser, K.E. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat. Med., 2012, 18(3), 344-346.
203. Ribas, A.; Camacho, L.H.; Lopez-Berestein, G.; Pavlov, D.; Bulanhagui, C.A.; Millham, R.; Comin-Anduix, B.; Reuben, J.M.; Seja, E.; Parker, C.A.; Sharma, A.; Glaspy, J.A.; Gomez-Navarro, J. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol., 2005, 23(35), 8968-8977.
204. Comin-Anduix, B.; Lee, Y.; Jalil, J.; Algazi, A.; de la Rocha, P.; Camacho, L.H.; Bozon, V.A.; Bulanhagui, C.A.; Seja, E.; Villanueva, A.; Straatsma, B.R.; Gualberto, A.; Economou, J.S.; Glaspy, J.A.; Gomez-Navarro, J.; Ribas, A. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J. Transl. Med., 2008, 6(1), 22.
205. Hodi, F.S.; Mihm, M.C.; Soiffer, R.J.; Haluska, F.G.; Butler, M.; Seiden, M.V.; Davis, T.; Henry-Spires, R.; Mac-Rae, S.; Willman, A.; Padera, R.; Jaklitsch, M.T.; Shankar, S.; Chen, T.C.; Korman, A.; Allison, J.P.; Dranoff, G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA, 2003, 100(8), 4712-4717.
206. Ansell, S.M.; Hurvitz, S.A.; Koenig, P.A.; LaPlant, B.R.; Kabat, B.F.; Fernando, D.; Habermann, T.M.; Inwards, D.J.; Verma, M.; Yamada, R.; Erlichman, C.; Lowy, I.; Timmerman, J.M. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res., 2009, 15(20), 6446-6453.
207. Yamazaki, N.; Kiyohara, Y.; Uhara, H.; Fukushima, S.; Uchi, H.; Shibagaki, N.; Tsutsumida, A.; Yoshikawa, S.; Okuyama, R.; Ito, Y.; Tokudome, T. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother. Pharmacol., 2015, 76(5), 997-1004.
208. Margolin, K.; Ernstoff, M.S.; Hamid, O.; Lawrence, D.; McDermott, D.; Puzanov, I.; Wolchok, J.D.; Clark, J.I.; Sznol, M.; Logan, T.F.; Richards, J.; Michener, T.; Balogh, A.; Heller, K.N.; Hodi, F.S. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol., 2012, 13(5), 459-465.
209. Yang, J.C.; Hughes, M.; Kammula, U.; Royal, R.; Sher-ry, R.M.; Topalian, S.L.; Suri, K.B.; Levy, C.; Allen, T.; Mav-roukakis, S. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother., 2007, 30(8), 825-830.
210. Royal, R.E.; Levy, C.; Turner, K.; Mathur, A.; Hughes, M.; Kammula, U.S.; Sherry, R.M.; Topalian, S.L.; Yang, J.C.; Lowy, I.; Rosenberg, S.A. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother., 2010, 33(8), 828-833.
211. Kwon, E.D.; Drake, C.G.; Scher, H.I.; Fizazi, K.; Bossi, A.; van den Eertwegh, A.J.; Krainer, M.; Houede, N.; Santos, R.; Mahammedi, H.; Ng, S.; Maio, M.; Franke, F.A.; Sundar, S.; Agarwal, N.; Bergman, A.M.; Ciuleanu, T.E.; Korbenfeld, E.; Sengeløv, L.; Hansen, S.; Logothetis, C.; Beer, T.M.; McHenry, M.B.; Gagnier, P.; Liu, D.; Gerrit-sen, W.R. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol., 2014, 15(7), 700-712.
212. Rizvi, N.A.; Mazières, J.; Planchard, D.; Stinchcombe, T.E.; Dy, G.K.; Antonia, S.J.; Horn, L.; Lena, H.; Minenza, E.; Mennecier, B.; Otterson, G.A.; Campos, L.T.; Gandara, D.R.; Levy, B.P.; Nair, S.G.; Zalcman, G.; Wolf, J.; Sou-quet, P.J.; Baldini, E.; Cappuzzo, F.; Chouaid, C.; Dowlati, A.; Sanborn, R.; Lopez-Chavez, A.; Grohe, C.; Huber, R.M.; Harbison, C.T.; Baudelet, C.; Lestini, B.J.; Rama-lingam, S.S. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (Check-Mate 063): a phase 2, single-arm trial. Lancet Oncol., 2015, 16(3), 257-265.
213. Herbst, R.S.; Baas, P.; Kim, D-W.; Felip, E.; Pérez-Gracia, J.L.; Han, J-Y.; Molina, J.; Kim, J-H.; Arvis, C.D.; Ahn, M-J.; Majem, M.; Fidler, M.J.; de Castro, G., Jr; Garrido, M.; Lubiniecki, G.M.; Shentu, Y.; Im, E.; Dolled-Filhart, M.; Garon, E.B. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet, 2016, 387(10027), 1540-1550.
214. Horinouchi, H.; Yamamoto, N.; Fujiwara, Y.; Sekine, I.; Nokihara, H.; Kubota, K.; Kanda, S.; Yagishita, S.; Wakui, H.; Kitazono, S.; Mizugaki, H.; Tokudome, T.; Tamura, T. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest. New Drugs, 2015, 33(4), 881-889.
215. Di Giacomo, A.M.; Ascierto, P.A.; Pilla, L.; Santinami, M.; Ferrucci, P.F.; Giannarelli, D.; Marasco, A.; Rivoltini, L.; Simeone, E.; Nicoletti, S.V.; Fonsatti, E.; Annesi, D.; Queirolo, P.; Testori, A.; Ridolfi, R.; Parmiani, G.; Maio, M. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol., 2012, 13(9), 879-886.
216. Arriola, E.; Wheater, M.; Galea, I.; Cross, N.; Maishman, T.; Hamid, D.; Stanton, L.; Cave, J.; Geldart, T.; Mulatero, C. Outcome and biomarker analysis from a multi-centre phase 2 study of ipilimumab in combination with carboplatin and etoposide (ICE) as first line therapy for extensive stage small cell lung cancer. J. Thorac. Oncol., 2016, 11(9), 1511-1521.
217. Jiang, B.S.; Beasley, G.M.; Speicher, P.J.; Mosca, P.J.; Morse, M.A.; Hanks, B.; Salama, A.; Tyler, D.S. Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. Ann. Surg. Oncol., 2014, 21(8), 2525-2531.
218. Yamazaki, N.; Uhara, H.; Fukushima, S.; Uchi, H.; Shibagaki, N.; Kiyohara, Y.; Tsutsumida, A.; Namikawa, K.; Okuyama, R.; Otsuka, Y.; Tokudome, T. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. Cancer Chemother. Pharmacol., 2015, 76(5), 969-975.
219. Di Giacomo, A.; Ascierto, P.; Queirolo, P.; Pilla, L.; Ridolfi, R.; Santinami, M.; Testori, A.; Simeone, E.; Guidoboni, M.; Maurichi, A. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the italian network for tumor biotherapy (NIBIT)-M1 phase II study. Ann. Oncol., 2015, 26(4), 798-803.